Download books file now Prescribing by Numbers: Drugs and the Definition of Disease – October 1, 2008 from 4shared, mediafire, hotfile, and mirror link
Review
Greene provides suggestions on how to address some of the problems inherent in medical prevention.
(
Choice)
Shows how the process of defining disease 'illustrates the porous relationship between the science and the marketing of health care.'
(Nina C. Ayub
Chronicle of Higher Education)
A gripping story... Greene warns us in his superb book that things are not always as they are claimed.
(Howard Spiro
Yale Journal for Humanities in Medicine)
This is, I believe, one of the best, and most significant, books published recently on the development of medical practice and the pharmaceutical industry in the USA in the second half of the twentieth century.
(Judy Slinn
Social History of Medicine)
Greene focuses on the question of how public health priorities became closely aligned with the pharmaceutical industry's marketing practices... Offers a nuanced description of the development of 'therapeutics of risk reduction' with multiple lines of influence, subtle power shifts, and gains and losses for patients and physicians.
(Arthur Daemmrich
Chemical Heritage)
Greene describes the relationship between advances in treatment, the incentives of manufacturers, and the effect on the public of increased attention to prevention... The risk-benefit trade-offs of the quantitative approach are complex, and Greene's historical revelations are timely.
(Kevin A. Schulman, M.D.
New England Journal of Medicine)
The interaction between medical science and industry has been fruitfully explored by several excellent historians... but Greene's intricate narratives extend their work.
(Marcia Meldrum
Isis)
I heartily recommend this book.
(Toine Pieters
Medical History)
By the end of Prescribing by Numbers, one realizes it is an excellent book to think with. Greene uses his case studies to juxtapose the therapeutics of risk with more contemporary health dilemmas.
(Gregory J. Higby
Pharmacy in History)
Greene's nuanced and lucid research yields new insight into the mechanisms that linked specific medications to the management of particular chronic diseases in the postwar era.
(Cynthia A. Connolly, PhD, RN
Nursing History Review)
An insightful, engrossing exploration of how our notions of 'disease' have evolved—with profound implications for understanding the health care of today and tomorrow.
(Jerry Avorn, M.D, Professor of Medicine, Harvard Medical School, author of
Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs)
What is remarkable about this book is not just the grace and assurance of Greene's writing, but the way Greene combines an insider's view of medical practice and pharmaceutical marketing with much broader social currents. It is an extraordinarily impressive work of scholarship.
(Carl Elliott, M.D., Ph.D., University of Minnesota Center for Bioethics, author of
Better than Well: American Medicine Meets the American Dream)
Greene’s historical account of our brave new world of drug-driven risk reduction is troubling and calls for some response. Both the scholarly depth and balanced tone of Prescribing by Numbers suggests that rather than simply rooting out bad actors and unethical practices, we must grapple with the very values and structural forces that are central to medical care and health today.
(Robert Aronowitz, M.D., History and Sociology of Science Department, University of Pennsylvania)
From the Back Cover
The second half of the twentieth century witnessed the emergence of a new model of chronic disease—diagnosed on the basis of numerical deviations rather than symptoms and treated on a preventive basis before any overt signs of illness develop—that arose in concert with a set of safe, effective, and highly marketable prescription drugs. Physician-historian Jeremy A. Greene examines the mechanisms by which drugs and chronic disease categories define one another within medical research, clinical practice, and pharmaceutical marketing, and he explores how this interaction has profoundly altered the experience, politics, ethics, and economy of health in late-twentieth-century America. His provocative analysis sheds light on the increasing presence of the subjectively healthy but highly medicated individual in the American medical landscape, suggesting how historical perspective can help to address the problems inherent in the program of pharmaceutical prevention.
"Greene describes the relationship between advances in treatment, the incentives of manufacturers, and the effect on the public of increased attention to prevention... The risk-benefit trade-offs of the quantitative approach are complex, and Greene's historical revelations are timely."— New England Journal of Medicine
"One of the best, and most significant, books published recently on the development of medical practice and the pharmaceutical industry in the U.S. in the second half of the twentieth century."— Social History of Medicine
"Greene focuses on the question of how public health priorities became closely aligned with the pharmaceutical industry's marketing practices... [and] offers a nuanced description of the development of 'therapeutics of risk reduction' with multiple lines of influence, subtle power shifts, and gains and losses for patients and physicians."— Chemical Heritage
"A gripping story... Greene warns us in his superb book that things are not always as they are claimed."— Yale Journal for Humanities in Medicine
Jeremy A. Greene is a fellow in the Department of Social Medicine at Harvard Medical School and a resident in the Department of Medicine at Brigham and Women’s Hospital.
See all Editorial Reviews
Direct download links available for Prescribing by Numbers: Drugs and the Definition of Disease – October 1, 2008